{"chunks": [{"type": "pdf", "chunk_number": 1, "pages": [{"page_number": 1, "text": "CENTER FOR DRUG EVALUATION AND \nRESEARCH \n \n \nAPPLICATION NUMBER: \n \n761365Orig1s000 \n \n \nOTHER ACTION LETTERS  \n "}, {"page_number": 2, "text": ""}, {"page_number": 3, "text": "BLA 761365\nPage 2\nU.S. Food and Drug Administration\nSilver Spring, MD 20993\nwww.fda.gov\nperformed according to the USP <71> compendial method and update the method \nprocedure in section 3.2.P.5.2 accordingly.\n2. The container closure integrity test (CCIT) method used for drug product stability \ntesting was validated for specificity and detection limit (refer to Table 2 of section \n3.2.P.8.3). However, the CCIT method is non-compendial and should also be \nvalidated for precision (repeatability, intermediate precision, and reproducibility) and \nrobustness (capacity of method to remain unaffected by deliberate variations in \nmethod parameters). Provide complete CCIT method validation results for the \nproposed dye ingress method. Refer to FDA Guidance for Industry: Analytical \nProcedures and Methods Validation for Drugs and Biologics, 2015.\n3. You plan  for commercial manufacture of IMAB362 \ndrug product. You evaluated\nProvide additional data and/or information to support that the \n is \ncapable of manufacturing IMAB362 drug product reproducibly.\nPRESCRIBING INFORMATION\nWe reserve comment on the proposed labeling until the application is otherwise \nadequate. We encourage you to review the labeling review resources on the \nPrescription Drug Labeling Resources1 and Pregnancy and Lactation Labeling Final \nRule2 websites, including regulations and related guidance documents and the Selected \nRequirements for Prescribing Information (SRPI) \u2212 a checklist of important format items \nfrom labeling regulations and guidances. \nCARTON AND CONTAINER LABELING\nWe reserve comment on the proposed labeling until the application is otherwise \nadequate.\nPROPRIETARY NAME\nPlease refer to correspondence dated, March 23, 2023, which addresses the proposed \nproprietary name, VYLOY. This name was found conditionally acceptable pending \napproval of the application in the current review cycle. Please resubmit the proposed \nproprietary name when you respond to all of the application deficiencies that have been \nidentified in this letter.\n1 https://www.fda.gov/drugs/laws-acts-and-rules/prescription-drug-labeling-resources \n2 https://www.fda.gov/drugs/labeling-information-drug-products/pregnancy-and-lactation-labeling-drugs-\nfinal-rule \nReference ID: 5304756\n(b) (4)\n(b) (4)\n(b) (4)\n(b) (4)"}, {"page_number": 4, "text": "BLA 761365\nPage 3\nU.S. Food and Drug Administration\nSilver Spring, MD 20993\nwww.fda.gov\nSAFETY UPDATE\nWhen you respond to the above deficiencies, include a safety update as described at \n21 CFR 314.50(d)(5)(vi)(b). The safety update should include data from all nonclinical \nand clinical studies/trials of the drug under consideration regardless of indication, \ndosage form, or dose level.\na. Describe in detail any significant changes or findings in the safety profile.\nb. When assembling the sections describing discontinuations due to adverse \nevents, serious adverse events, and common adverse events, incorporate new \nsafety data as follows:\n\u2022 Present new safety data from the studies/clinical trials for the proposed \nindication using the same format as in the original submission.\n\u2022 Present tabulations of the new safety data combined with the original \napplication data.\n\u2022 Include tables that compare frequencies of adverse events in the original \napplication with the retabulated frequencies described in the bullet above.\n\u2022 For indications other than the proposed indication, provide separate tables for \nthe frequencies of adverse events occurring in clinical trials.\nc. Present a retabulation of the reasons for premature trial discontinuation by \nincorporating the drop-outs from the newly completed trials. Describe any new \ntrends or patterns identified.\nd. Provide case report forms and narrative summaries for each subject who died \nduring a clinical trial or who did not complete a trial because of an adverse event. \nIn addition, provide narrative summaries for serious adverse events.\ne. Describe any information that suggests a substantial change in the incidence of \ncommon, but less serious, adverse events between the new data and the original \napplication data.\nf. Provide updated exposure information for the clinical studies/trials (e.g., number \nof subjects, person time).\ng. Provide a summary of worldwide experience on the safety of this drug. Include \nan updated estimate of use for drug marketed in other countries.\nh. Provide English translations of current approved foreign labeling not previously \nsubmitted.\nReference ID: 5304756"}, {"page_number": 5, "text": "BLA 761365\nPage 4\nU.S. Food and Drug Administration\nSilver Spring, MD 20993\nwww.fda.gov\nOTHER\nWithin one year after the date of this letter, you are required to resubmit or take other \nactions available under 21 CFR 601.3(b). If you do not take one of these actions, we \nmay consider your lack of response a request to withdraw the application under \n21 CFR 601.3(c). You may also request an extension of time in which to resubmit the \napplication. \nA resubmission must fully address all the deficiencies listed in this letter and should be \nclearly marked with \"RESUBMISSION\" in large font, bolded type at the beginning of the \ncover letter of the submission. The cover letter should clearly state that you consider \nthis resubmission a complete response to the deficiencies outlined in this letter. A partial \nresponse to this letter will not be processed as a resubmission and will not start a new \nreview cycle. \nYou may request a meeting or teleconference with us to discuss what steps you need to \ntake before the application may be approved. If you wish to have such a meeting, \nsubmit your meeting request as described in the draft guidance for industry Formal \nMeetings Between the FDA and Sponsors or Applicants of PDUFA Products.\nThe product may not be legally marketed until you have been notified in writing that this \napplication is approved.\nIf you have any questions, call Nataliya Fesenko, Pharm.D., Senior Regulatory Health \nProject Manager, at (240) 402-6376.\nSincerely,\n{See appended electronic signature page}\nPaul G. Kluetz, M.D.\nSupervisory Associate Director (Acting)\nOffice of Oncologic Diseases\nOffice of New Drugs\nCenter for Drug Evaluation & Research\nReference ID: 5304756"}, {"page_number": 6, "text": "--------------------------------------------------------------------------------------------\nThis is a representation of an electronic record that was signed\nelectronically. Following this are manifestations of any and all\nelectronic signatures for this electronic record.\n--------------------------------------------------------------------------------------------\n/s/\n------------------------------------------------------------\nPAUL G KLUETZ\n01/04/2024 04:42:34 PM\nSignature Page 1 of 1\nReference ID: 5304756"}], "token_count": 674}]}